1. Home
  2. DXLG vs BYSI Comparison

DXLG vs BYSI Comparison

Compare DXLG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.52

Market Cap

33.6M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.47

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
BYSI
Founded
1976
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6M
31.4M
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
DXLG
BYSI
Price
$0.52
$0.47
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $1.13
N/A
AVG Volume (30 Days)
132.2K
★ 282.5K
Earning Date
12-03-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $435,017,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.48
$49.96
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.36
$0.47
52 Week High
$1.58
$2.44

Technical Indicators

Market Signals
Indicator
DXLG
BYSI
Relative Strength Index (RSI) 54.62 32.91
Support Level $0.46 N/A
Resistance Level $0.59 $0.80
Average True Range (ATR) 0.04 0.07
MACD 0.02 -0.02
Stochastic Oscillator 83.14 6.99

Price Performance

Historical Comparison
DXLG
BYSI

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: